ACS Applied Materials & Interfaces · 2016 · 170 citations · 26 references
MedicineOncologyPharmacologyNanoparticle Drug DeliveryRadionuclide TherapyTheranosticsNanomedicinePhotodynamic TherapyRadiation TherapyRadiopharmaceutical TherapyRadiopharmaceuticalsTargeted Radionuclide TherapyCancer NanotherapyCell Viability AssaysIn Vivo StudiesMesoporous Silica NanomaterialsMesoporous Silica NanoparticlesSilica-based NanoparticlesTissue PenetrationZirconium-89 Labeling
Traditional photodynamic therapy (PDT) requires external light to activate photosensitizers for therapeutic purposes. However, the limited tissue penetration of light is still a major challenge for this method. To overcome this limitation, we report an optimized system that uses Cerenkov radiation for PDT by using radionuclides to activate a well-known photosensitizer (chlorin e6, Ce6). By taking advantage of hollow mesoporous silica nanoparticles (HMSNs) that can intrinsically radiolabel an oxophilic zirconium-89 ( 89 Zr, t 1/2 = 78.4 h) radionuclide, as well as possess great drug loading capacity, Ce6 can be activated by Cerenkov radiation from 89 Zr in the same nanoconstruct. In vitro cell viability experiments demonstrated dose-dependent cell deconstruction as a function of the concentration of Ce6 and 89 Zr. In vivo studies show inhibition of tumor growth when mice were subcutaneously injected with [ 89 Zr]HMSN-Ce6, and histological analysis of the tumor section showed damage to tumor tissues, implying that reactive oxygen species mediated the destruction. This study offers a way to use an internal radiation source to achieve deep-seated tumor therapy without using any external light source for future applications.
26
Gamma-H2AX - a novel biomarker for DNA double-strand breaks.
Linda J Kuo, Li‐Xi Yang · PubMed · 2008 · 1.2K citations
Fadlo R. Khuri, John Nemunaitis, Ian Ganly et al. · Nature Medicine · 2000 · 1.1K citations
Medicine, Oncology, Chemotherapy +8